Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vecGlobeNewsWire • 04/23/23
Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMDGlobeNewsWire • 04/18/23
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual MeetingGlobeNewsWire • 04/17/23
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial UpdateGlobeNewsWire • 03/30/23
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)GlobeNewsWire • 11/04/22
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual MeetingGlobeNewsWire • 10/27/22
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMDGlobeNewsWire • 09/30/22
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/27/22
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine SummitGlobeNewsWire • 09/23/22
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular DegenerationGlobeNewsWire • 09/14/22
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/08/22
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company ShowcaseGlobeNewsWire • 08/26/22
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual ConferenceGlobeNewsWire • 08/10/22
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMDGlobeNewsWire • 07/15/22